Actinium Presents Data Demonstrating Actimab-A In Combination With Leading Menin Inhibitors With Its ARC Actimab-A In Acute Myeloid Leukemia At 2024 EHA Congress

6/17/24 8:11:03 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATNM alert in real time by email

- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors

- Combination with leading menin inhibitor demonstrates acute myeloid leukemia cell death and significant tumor elimination not achieved with monotherapy

- Menin combination expands backbone potential of Actimab-A in acute myeloid leukemia that already includes chemotherapy, venetoclax and FLT3 inhibitors

Get the next $ATNM alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ATNM

Date	Price Target	Rating	Analyst
8/7/2024	$16.00 → $2.00	Buy → Neutral	B. Riley Securities
5/14/2024	$25.00	Overweight	Stephens
9/6/2023	$11.60	Buy	HSBC Securities
2/21/2023		Outperform → Mkt Perform	William Blair
9/8/2022	$20.00	Overweight	Cantor Fitzgerald
8/25/2022	$16.00	Buy	B. Riley Securities
8/3/2021	$57.00 → $45.00	Buy	HC Wainwright & Co.

More analyst ratings

$ATNM
Financials

Live finance-specific insights

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia
- Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm - In patients achieving 6-month dCR with Iomab-b, 1-year survival of 92% and 2-year survival of 60% was achieved; median overall survival (OS) has not been reached in these patients - Iomab-B demonstrated significant improvement in Event Free Survival (EFS) with a Hazard Ratio = 0.22, p<0.0001 - Iomab-B doubled 1-year survival and median overall survival compared to control arm patients who did not crossover - Iomab-B was
2/18/23 4:30:00 PM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care
Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023
- Late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023, to feature Iomab-B SIERRA Pivotal Trial results - Investor call at 6:00 PM EST on Saturday, February 18, 2023, to highlight full results from the Phase 3 SIERRA trial NEW YORK, Feb. 14, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies, today announced its presence at the upcoming Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) being held February 15 – 19,
2/14/23 7:30:00 AM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care
Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings
- Full Iomab-B SIERRA data set to be presented in late-breaker presentation at 5:00 PM EST on Saturday, February 18, 2023 - Company to host conference call and webcast on Saturday, February 18, 2023, at 6:00 PM EST - SIERRA trial met primary endpoint with high statistical significance (p<0.0001) - Company to host Iomab-B KOL event with Dr. Sergio Giralt of Memorial Sloan Kettering Cancer Center at 8:00 AM EST on February 28, 2023 NEW YORK, Jan. 12, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that data from its pivotal Phase 3 SIERRA trial of Iomab-B have been accepted as
1/12/23 8:00:00 AM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care

$ATNM
Press Releases

Fastest customizable press release news feed in the world

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
11/4/24 7:30:00 AM ET
$ATNM
$AVTX
$RDHL
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
Iomab-B is the first CD45 targeted radiotherapy for conditioning in development to enable potentially curative bone marrow transplant and represents an alternative to chemotherapy-based approachesSIERRA achieved durable Complete Remission primary endpoint and Event-Free Survival secondary endpoint with high statistical significanceIomab-B was well tolerated in the older, heavily pretreated relapsed/refractory AML patients with active disease enrolled in the SIERRA trialActinium to seek strategic partner for Iomab-B for further development in the U.S. following completion of interactions with FDA for additional head-to-head clinical trial to demonstrate overall survival benefitNEW YORK, Sept.
9/20/24 8:00:00 AM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpointAdditional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filingActinium to request a meeting with the FDA to further discuss specifics of additional trialActinium will seek strategic partner for Iomab-B in the U.S. following completion of FDA interactions and focus development efforts on Actimab-A, Iomab-ACT and preclinical programsNEW YORK, Aug. 5, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) ("Actinium" or the "Company"), a leader in the devel
8/5/24 7:00:00 AM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
- Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors - Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu
11/4/24 7:30:00 AM ET
$ATNM
$AVTX
$RDHL
$TENX
Biotechnology: Pharmaceutical Preparations
Health Care
Coya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
Dr. Swaminathan will be responsible for establishing and leading business development, leveraging his expertise in licensing, transactions, and establishing strategic collaborations within the biotechnology and pharmaceutical industries. In his two prior companies serving as Chief Business Officer, Dr. Swaminathan demonstrated strong deal making ability - At Alteogen, he executed $3.8 billion and $1.4 billion deals with two top ten global pharmaceutical companies, increasing the value of the company approximately 10-fold, from $400 million to $4 billion. At Actinium, within a year of his hiring, he executed the largest deal in their history, worth $452 million for commercial rights of
3/27/23 7:00:00 AM ET
$ATNM
$COYA
Biotechnology: Pharmaceutical Preparations
Health Care
Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization
-Caroline joins Actinium from Novartis where she served as Portfolio General Manager, US Oncology-Proven commercial leadership experience spans hematology, oncology and rare diseases at Novartis, Glaxo SmithKline, Bristol Myers Squibb, ViroPharma and Merck & Co. NEW YORK, Nov. 2, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced the appointment of Caroline Yarbrough as Chief Commercial Officer. Caroline joins Actinium from Novartis where she most recently served as Portfolio General Manager, US Oncology, with full P&L responsibility of a diverse portfolio of brands and development
11/2/22 8:17:00 AM ET
$ATNM
Biotechnology: Pharmaceutical Preparations
Health Care

Actinium Presents Data Demonstrating Actimab-A In Combination With Leading Menin Inhibitors With Its ARC Actimab-A In Acute Myeloid Leukemia At 2024 EHA Congress

Chat with this insight

Recent Analyst Ratings for $ATNM

$ATNM Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Actinum Pharma downgraded by B. Riley Securities with a new price target

Stephens initiated coverage on Actinum Pharma with a new price target

HSBC Securities initiated coverage on Actinum Pharma with a new price target

$ATNM Financials

Live finance-specific insights

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

Actinium to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings on Saturday, February 18, 2023

Actinium Announces Phase 3 Iomab-B SIERRA Data Accepted for Late-Breaker Presentation at the Transplantation & Cellular Therapy Tandem Meetings

$ATNM Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Almenoff June Sherie

SEC Form 3 filed by new insider Almenoff June Sherie

SEC Form 4 filed by Nicholson, C. David

$ATNM Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

SEC Form SC 13G filed by Actinium Pharmaceuticals Inc. (Delaware)

Amendment: SEC Form SC 13G/A filed by Actinium Pharmaceuticals Inc. (Delaware)

$ATNM Market Insights

Live Market Insights

Actinium Pharmaceuticals Announces FDA Clearance For IND Application To Study Iomab-ACT As Targeted Conditioning Prior To Bone Marrow Transplant In Sickle Cell Disease Patients

HC Wainwright & Co. Reiterates Buy on Actinium Pharma, Maintains $50 Price Target